379 related articles for article (PubMed ID: 31267559)
21. Emerging phagocytosis checkpoints in cancer immunotherapy.
Liu Y; Wang Y; Yang Y; Weng L; Wu Q; Zhang J; Zhao P; Fang L; Shi Y; Wang P
Signal Transduct Target Ther; 2023 Mar; 8(1):104. PubMed ID: 36882399
[TBL] [Abstract][Full Text] [Related]
22. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
[TBL] [Abstract][Full Text] [Related]
23. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Kim A; Han CJ; Driver I; Olow A; Sewell AK; Zhang Z; Ouyang W; Egen JG; Yu X
J Immunol; 2019 Aug; 203(4):1076-1087. PubMed ID: 31253728
[TBL] [Abstract][Full Text] [Related]
24. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
25. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.
McCracken MN; Cha AC; Weissman IL
Clin Cancer Res; 2015 Aug; 21(16):3597-601. PubMed ID: 26116271
[TBL] [Abstract][Full Text] [Related]
26. Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes.
Mohammed F; Stones DH; Willcox BE
J Immunol Methods; 2019 Jan; 464():47-56. PubMed ID: 30365927
[TBL] [Abstract][Full Text] [Related]
27. Don't eat me/eat me signals as a novel strategy in cancer immunotherapy.
Khalaji A; Yancheshmeh FB; Farham F; Khorram A; Sheshbolouki S; Zokaei M; Vatankhah F; Soleymani-Goloujeh M
Heliyon; 2023 Oct; 9(10):e20507. PubMed ID: 37822610
[TBL] [Abstract][Full Text] [Related]
28. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.
Bernal M; Ruiz-Cabello F; Concha A; Paschen A; Garrido F
Cancer Immunol Immunother; 2012 Sep; 61(9):1359-71. PubMed ID: 22833104
[TBL] [Abstract][Full Text] [Related]
29. Phagocytosis checkpoints as new targets for cancer immunotherapy.
Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL
Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760
[TBL] [Abstract][Full Text] [Related]
30. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition.
Tal MC; Torrez Dulgeroff LB; Myers L; Cham LB; Mayer-Barber KD; Bohrer AC; Castro E; Yiu YY; Lopez Angel C; Pham E; Carmody AB; Messer RJ; Gars E; Kortmann J; Markovic M; Hasenkrug M; Peterson KE; Winkler CW; Woods TA; Hansen P; Galloway S; Wagh D; Fram BJ; Nguyen T; Corey D; Kalluru RS; Banaei N; Rajadas J; Monack DM; Ahmed A; Sahoo D; Davis MM; Glenn JS; Adomati T; Lang KS; Weissman IL; Hasenkrug KJ
mBio; 2020 Jun; 11(3):. PubMed ID: 32576678
[TBL] [Abstract][Full Text] [Related]
32. M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy.
Zhao W; Hu X; Li W; Li R; Chen J; Zhou L; Qiang S; Wu W; Shi S; Dong C
Small; 2021 Apr; 17(13):e2007051. PubMed ID: 33599061
[TBL] [Abstract][Full Text] [Related]
33. Chicken novel leukocyte immunoglobulin-like receptor subfamilies B1 and B3 are transcriptional regulators of major histocompatibility complex class I genes and signaling pathways.
Truong AD; Hong Y; Lee J; Lee K; Tran HTT; Dang HV; Nguyen VK; Lillehoj HS; Hong YH
Asian-Australas J Anim Sci; 2019 May; 32(5):614-628. PubMed ID: 30381742
[TBL] [Abstract][Full Text] [Related]
34. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes.
Roehle K; Qiang L; Ventre KS; Heid D; Ali LR; Lenehan P; Heckler M; Crowley SJ; Stump CT; Ro G; Godicelj A; Bhuiyan AM; Yang A; Quiles Del Rey M; Biary T; Luoma AM; Bruck PT; Tegethoff JF; Nopper SL; Li J; Byrne KT; Pelletier M; Wucherpfennig KW; Stanger BZ; Akin JJ; Mancias JD; Agudo J; Dougan M; Dougan SK
Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011631
[TBL] [Abstract][Full Text] [Related]
35. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
36. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
[TBL] [Abstract][Full Text] [Related]
37. Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.
Haworth KB; Arnold MA; Pierson CR; Leddon JL; Kurmashev DK; Swain HM; Hutzen BJ; Roberts RD; Cripe TP
Pediatr Blood Cancer; 2016 Apr; 63(4):618-26. PubMed ID: 26575538
[TBL] [Abstract][Full Text] [Related]
38. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
39. Just eat it: A review of CD47 and SIRP-α antagonism.
Oronsky B; Carter C; Reid T; Brinkhaus F; Knox SJ
Semin Oncol; 2020; 47(2-3):117-124. PubMed ID: 32517874
[TBL] [Abstract][Full Text] [Related]
40. Insights into CD47/SIRPα axis-targeting tumor immunotherapy.
Zhang X; Fan J; Ju D
Antib Ther; 2018 Sep; 1(2):37-42. PubMed ID: 34056543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
